Updates

Latest news, events, resources, and thought pieces from the Exchange's blog

LILETTA® levonorgestrel-releasing intrauterine system now FDA-approved for use for up to 6 years

Post written by Yadurshini Raveendran, FHI 360 Medicines360 and Allergan announced the U.S. Food and Drug Administration (FDA) approved the extension of LILETTA® (levonorgestrel-releasing intrauterine system, LNG-IUS) for pregnancy prevention for up to 6 years, making it the longest duration LNG-IUS and second longest reversible contraceptive in the U.S. The FDA approval was based on […]...

When are commodities not just “commodities”?

Post written by Mukul Taparia, Managing Director, Pregna International “Commodity” is a term commonly used by our community to refer to a vast range of products, from contraceptives and menstrual pads at one end, to office products and furniture at the other. Everyone has their own unique understanding of the term, a study discovered some years […]...

The Initiative for Multipurpose Prevention Technologies (IMPT) Ten-Year Retrospective Report

Post written by Tishina Okegbe, FHI 360 Imagine using one product or method to safeguard against an unwanted pregnancy or a sexually transmitted infection. Well, there’s a technology for that – more specifically, multipurpose prevention technologies, or MPTs. MPTs serve a dual purpose in addressing the sexual and reproductive health needs of women— preventing against […]...

Pressing Pause on Your Fertility: Contraception via Egg Hibernation

Post written by Tishina Okegbe, FHI 360 Women currently have several methods of reversible contraception to choose from, including hormonal options such as the implant, injectables and pills, and nonhormonal options such as the condom and the copper intrauterine device. Though this is true, there are some 214 million women in lower-and middle-income countries who […]...

The Demographic and Health Surveys (DHS) Program Updates Questionnaires

The Demographic and Health Surveys (DHS) Program has updated its questionnaires for DHS-8. Since 1984, the DHS Program has provided technical assistance to more than 400 surveys in 90 countries, advancing global understanding of health and population trends in developing countries. Specifically, the DHS Program collects and disseminates nationally representative data on fertility, family planning, […]...

NICHD Releases Five-Year Strategic Plan

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has publicly released its updated five-year Strategic Plan. This strategic plan was developed through a consultative process with stakeholders to guide the institute’s activities over the next five years. It proposes key scientific and public health priorities to advance research, methods to enhance scientific […]...

More on the blog

Why Contraceptive Innovation?

Despite the availability of various contraceptive methods, more than 200 million women in developing countries want to avoid or delay pregnancy yet are not using an effective family planning method. For some of these women, access to contraception is limited. For others, currently available methods do not meet their needs or preferences or are unaffordable. Innovative solutions are needed in the areas of product development, registration, pricing, and introduction to address these barriers.

Join the exchange and become part of the solution!

Visit our resource library for additional information about the need for contraceptive innovation.


Resources

A one-stop shop for resources related to contraceptive research and development

The CTI Exchange offers resources about contraceptive research and development, including information about products currently in development, preclinical and clinical research, and opportunities for future investment. This easily searchable resource library also includes information about regulatory requirements, quality assurance standards, intellectual property, and product introduction strategies, as well as tools for advocacy.

View all resources


Featured Resources

Other key resources related to contraceptive research and development

Calliope, the Contraceptive Pipeline Database, includes information on potential contraceptive targets and leads, products in pre-clinical and clinical development, and a selection of novel and long-acting products with limited market availability.
CAPRI, the Contraceptive Active Pharmaceutical Ingredient Database, lists biological and chemical properties for 27 active pharmaceutical ingredients found in contraceptives, along with data on their pharmacology, toxicology, impurities, metabolites, and use in marketed products.
Contraceptive Drug Interactions is a database that catalogues potential interactions between contraceptive drugs and drugs from other therapeutic classes. Changes in drug pharmacokinetics, effectiveness, and adverse effects are provided.

Contribute

We want you to join the exchange!

The CTI Exchange looks to partners to help generate and share resources. Contact us with your ideas, materials, or questions, or sign up to receive more information. We also encourage you to provide your feedback

twittermail